[A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
To compare the results and side effects in treating uterine leiomyoma with gonadotrophin releasing hormone agonist (GnRH-a) or mifepristone. 75 patients with uterine leiomyoma who had clinical symptoms and diagnosed by Bcan were divided into two groups. The GnRH-a group (30 patients) was treated by injection of GnRH-a 150 micrograms/day subcutaneously for three months, and the mifepristone group (45 patients) was treated by mifepristone 12.5 mg/day po for three months. The clinical symptoms improved obviously in both groups. The volume of leiomyoma reduced 20.0% or more in 90.0% (27/30) of the patients in GnRH-a group, while it was 91.1% (41/45) in mifepristone group. However, the recurrent rates were 40.0% and 17.8% in the 2 groups. It suggested that mifepristone is a more practical and hopeful drug in treating uterine leiomyoma.